A Proposed Definition of Rare Diseases for China: From the Perspective of Return on Investment in New Orphan Drugs

Orphanet Journal of Rare Diseases - United Kingdom
doi 10.1186/s13023-015-0241-x
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

First International South Caucasian Conference on Rare Diseases and Orphan Drugs

European Journal of Pediatrics
Child HealthPediatricsPerinatology
2010English

Pivotal Studies of Orphan Drugs Approved for Neurological Diseases

Annals of Neurology
Neurology
2009English

Is the Current Approach to Reviewing New Drugs Condemning the Victims of Rare Diseases to Death? A Call for a National Orphan Drug Review Policy

CMAJ
Medicine
2006English

Php325 - Orphan Drugs‘ Market Access Challenges in Europe From a German Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

New Drugs for Mental Diseases?: New Diseases for Old Drugs?

Journal of the Royal Society of Medicine
Medicine
1987English

Multi-Criteria Decision Analysis (MCDA): Testing a Proposed McDa Model for Orphan Drugs

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Journal of Rare Cardiovascular Diseases: “Conquering New Territories” – A New Educational Program on Rare Diseases for Medical Acolytes

Journal of Rare Cardiovascular Diseases
Cardiovascular MedicineCardiology
2014English

The Analysis of Return on Investment of Trade in Serbia: Actual Situation and Perspective

Proceedings for Social Sciences Matica Srpska
2018English

Psy180 - Uk Health Technology Assessment of Orphan Drugs for Rare Oncology Versus Rare Disease: Does Orphan Designation Make Any Difference in Hta Process?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy